![Anna Berkenblit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anna Berkenblit
Directeur/Membre du Conseil chez
SURROZEN, INC.
Fortune : 51 994 $ au 31/07/2026
Profil
Anna Berkenblit currently serves as Director at Surrozen Operating, Inc. since 2019, Independent Director at Surrozen, Inc. since 2018, Director at Nested Therapeutics, Inc., and Chief Scientific & Medical Officer at Pancreatic Cancer Action Network, Inc. Former roles include Chief Medical Officer & Senior Vice President at ImmunoGen, Inc. from 2019 to 2023, Vice President at Pfizer Inc. from 2007 to 2011, Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc. from 2011 to 2013, and Senior Vice President-Clinical Development at H3 Biomedicine, Inc. from 2013 to 2015.
Education includes graduate degrees from Harvard University and Massachusetts Institute of Technology, an undergraduate degree from Yale University, and a doctorate from Harvard Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SURROZEN INC 0,02% | 13/05/2026 | 2 341 ( 0,02% ) | 51 994 $ | 31/07/2026 |
Postes actifs de Anna Berkenblit
| Sociétés | Poste | Début |
|---|---|---|
| SURROZEN, INC. | Directeur/Membre du Conseil | 01/08/2018 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Directeur/Membre du Conseil | 14/03/2019 |
Nested Therapeutics, Inc.
 Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery biotechnology company | Directeur/Membre du Conseil | - |
Pancreatic Cancer Action Network, Inc.
 Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Operates a charity which focuses on the early diagnosis of pancreatic cancer | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Anna Berkenblit
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 31/08/2023 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Corporate Officer/Principal | 01/01/2015 |
| AVEO PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2013 |
| PFIZER INC. | Corporate Officer/Principal | 01/09/2011 |
Formation de Anna Berkenblit
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops cancer therapeutics | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pancreatic Cancer Action Network, Inc.
Pancreatic Cancer Action Network, Inc. Medical/Nursing ServicesHealth Services Operates a charity which focuses on the early diagnosis of pancreatic cancer | Health Services |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Commercial Services |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Surrozen, Inc.
 Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery biotechnology company | Commercial Services |
